- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT05332002
sFOLFOXIRI i avancerad gastroesofageal cancer, (SAGE)
En fas II-studie av sFOLFOXIRI i avancerad gastroesofageal cancer (SAGE)
The primary objective is to determine the clinical efficacy of treatment regimen in terms of objective response rate (ORR). The secondary objectives is to determine the clinical efficacy of the study treatment in terms of progression free survival (PFS) and overall survival (OS). Additionally, to characterize the safety and toxicity profile of the study treatment as measured by the adverse event rates.
Studieöversikt
Status
Betingelser
Intervention / Behandling
Detaljerad beskrivning
The overall purpose of this protocol is to serve as a Single Arm Phase II trial of a four week alternating FOLFOX and FOLFIRI (sFOLFOXIRI), with or without nivolumab, in advanced human epidermal growth factor receptor two (HER2) negative gastric and esophageal cancers (GEC). This study evaluates the hypothesis that the use of sFOLFOXIRI in gastroesophageal cancer (GEC) will increase response rates beyond that expected with FOLFOX, while maintaining acceptable tolerability. The primary endpoint of this study is the objective response rate (ORR) while the key secondary endpoints include the progression free survival (PFS), overall survival (OS), and adverse event (AE) rates. The goal of this study is to establish the activity level of sFOLFOXIRI, with the thought that this could be further developed in the metastatic and/or peri-operative space if a sufficiently interesting degree of efficacy is observed.
Studietyp
Inskrivning (Beräknad)
Fas
- Fas 2
Kontakter och platser
Studiekontakt
- Namn: Patrick Boland, MD
- Telefonnummer: (732)235-2465
- E-post: pb564@cinj.rutgers.edu
Studieorter
-
-
New Jersey
-
Hamilton, New Jersey, Förenta staterna, 08690
- Rekrytering
- RWJBarnabas Health - Robert Wood Johnson University Hospital
-
Kontakt:
- Patrick Boland, MD
-
Lakewood, New Jersey, Förenta staterna, 08701
- Rekrytering
- RWJBarnabas Health - Monmouth Medical Center Southern Campus
-
Kontakt:
- Patrick Boland, MD
-
Long Branch, New Jersey, Förenta staterna, 07740
- Rekrytering
- RWJBarnabas Health - Monmouth Medical Center
-
Kontakt:
- Patrick Boland, MD
-
New Brunswick, New Jersey, Förenta staterna, 08903
- Rekrytering
- Rutgers Cancer Institute of New Jersey
-
Kontakt:
- Patrick Boland, MD
-
New Brunswick, New Jersey, Förenta staterna, 08903
- Rekrytering
- RWJBarnabas Health - Robert Wood Johnson University Hospital, Somerset
-
Kontakt:
- Patrick Boland, MD
-
Newark, New Jersey, Förenta staterna, 07112
- Rekrytering
- RWJBarnabas Health - Newark Beth Israel Medical Center
-
Kontakt:
- Patrick Boland, MD
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
-
Histologically and/or cytologically confirmed metastatic or unresectable adenocarcinoma of esophageal, gastroesophageal junction or gastric origin
-
Tumor is HER2 negative by standard local testing methodology
-
Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 - 2
-
Measurable disease by response evaluation criteria in solid tumors (RECIST) v1.1
-
No prior systemic therapy for the present cancer given in the metastatic setting and > 6 months from administration of peri-operative chemotherapy, if applicable
o Note: up to two prior cycles of mFOLFOX6 for the present illness is permitted if patients otherwise qualify for the study with adequate baseline imaging
-
At least 18 years of age
-
Adequate bone marrow and organ functions as defined by:
-
Absolute neutrophil count ≥ 1500 cells/ μL
-
Hemoglobin ≥ 8 g/ dL
-
Platelets > 100,000 / μL
-
Creatinine ≤ 1.5 x upper limit of normal (ULN) OR creatinine clearance ≥ 30 mL/min by Cockroft-Gault
-
Total bilirubin ≤ ULN
-
Aspartate aminotransferase (AST)/ Alanine aminotransferase (ALT) < 2.5 x ULN, unless with liver metastases and then must be <5 x ULN of normal
-
Women and men of childbearing potential must agree to use adequate contraception (hormonal or barrier method of birth control or abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect pregnancy on study, she must notify her treating physician immediately.
-
Ability to understand the nature of this study protocol and give written informed consent.
-
Willingness and ability to comply with scheduled visits, treatment plans laboratory tests and other study procedures.
Exclusion Criteria:
- Receipt of any investigational agents at the time of registration
- Known, untreated brain metastases
- Grade two or greater peripheral neuropathy
- Presence of any additional active malignancy within the past three years where the malignancy is at least reasonably likely to later the course of therapy, require systemic therapy or interfere with imaging assessments
- For those patients who are going to receive nivolumab
- No active use of systemic corticosteroids at the time of enrollment, at a dose equivalent of 10 mg/day or prednisone
- Clinically significant autoimmune disease which is active or has required systemic immunosuppression within the last two years
- Prior organ transplant or bone marrow transplant
- History of interstitial lung disease or pneumonitis
- Uncontrolled intercurrent illness, including significant active infection, symptomatic congestive heart failure, unstable angina or active arrhythmia
- Major surgery within the four weeks prior to initiation of study treatment
- A history of allergy or hypersensitivity to any of the study drugs
- Any additional significant medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from fully participating in the study
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: N/A
- Interventionsmodell: Enskild gruppuppgift
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Övrig: 4week alternating FOLFOX and a combination chemotherapy regime FOLFIRI (sFOLFOXIRI),
A cycle will constitute 28 days of treatment, which will consist of one chemotherapy combination, either FOLFOX or FOLFIRI as below:
|
This is a Single Arm Phase II trial of q4week alternating FOLFOX and FOLFIRI (sFOLFOXIRI), with or without nivolumab, in advanced human epidermal growth factor receptor 2 (HER2) negative gastric and esophageal cancers (GEC). The study treatment is a chemotherapy combination of either FOLFOX or FOLFIRI as below:
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Priser för negativa händelser
Tidsram: Tre år
|
Tre år
|
|
|
Objective Response Rate (ORR) as measured by Response Evaluation Criteria in Solid Tumors ( RECIST) criteria version 1.1
Tidsram: Three Years
|
To determine the clinical efficacy of treatment regimen in terms of objective response rate. |
Three Years
|
|
Progression Free Survival (PFS)
Tidsram: Three Years
|
To determine the clinical efficacy of the study treatment in terms of progressive free survival. |
Three Years
|
|
Overall Survival (OS)
Tidsram: Three Years
|
To determine the clinical efficacy of the study treatment in terms of overall survival. |
Three Years
|
Samarbetspartners och utredare
Utredare
- Huvudutredare: Patrick Boland, MD, Rutgers Cancer Institute of New Jersey
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- 072204
- Pro2022000268 (Annan identifierare: Rutgers Cancer Institute of New Jersey)
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
produkt tillverkad i och exporterad från U.S.A.
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .